Hospital
ST. Mary's Medical Center INC
ST. Mary's Medical Center INC was paid $47.59M by Medicaid between Jan 2018 and Dec 2024, across 370 billing codes. Its largest line is 99285, emergency room visit (most serious) — 18% of everything it billed.
33Billing provider infoST. MARY'S MEDICAL CENTER INC
HUNTINGTON, WV 25702
HUNTINGTON, WV 25702
33aNPI1164492195assigned 01/24/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$47.59M
24GClaims1,482,562
24DCodes billed370
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#6 of 26
Median peer was paid$18.33M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 205,515 | $10.53M | |
| 2019 | 151,526 | $6.48M | |
| 2020 | 216,746 | $7.73M | |
| 2021 | 223,917 | $5.96M | |
| 2022 | 185,096 | $5.27M | |
| 2023 | 281,067 | $6.42M | |
| 2024incomplete | 218,695 | $5.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 31,807 | 27,176 | $8.47M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 44,154 | 40,213 | $4.77M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.6% | 49,716 | 46,338 | $3.61M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 10,260 | 9,143 | $2.14M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.5% | 20,248 | 16,075 | $1.64M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 10,572 | 9,456 | $1.27M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.3% | 5,066 | 4,628 | $1.09M |
| 80053 | Comprehensive metabolic panel | 2.2% | 111,782 | 91,741 | $1.05M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 22,023 | 17,646 | $1.04M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 106,593 | 87,588 | $715K |
| 93458 | 1.5% | 518 | 444 | $693K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 44,446 | 37,787 | $629K |
358 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 27,163 | $628K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 11,717 | $593K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.1% | 2,939 | $536K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 8,416 | $534K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,099 | $469K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,519 | $449K |
| 84484 | <1% | 33,034 | $435K | |
| 85027 | <1% | 21,274 | $410K | |
| 83735 | <1% | 40,850 | $389K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 13,645 | $380K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,397 | $375K |
| J2704 | Injection, propofol, 10 mg | <1% | 7,759 | $373K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 4,683 | $368K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 8,292 | $360K |
| C1769 | Guide wire | <1% | 2,527 | $337K |
| 36415 | Collection of venous blood by venipuncture | <1% | 56,226 | $332K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 18,907 | $331K |
| 83690 | <1% | 43,546 | $297K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,479 | $284K |
| 85730 | <1% | 27,611 | $282K | |
| 71045 | Radiologic examination, chest; single view | <1% | 20,530 | $272K |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | <1% | 1,258 | $267K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,379 | $266K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,261 | $256K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,669 | $244K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,729 | $243K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,345 | $242K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,188 | $237K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,480 | $236K |
| 80074 | <1% | 4,879 | $227K | |
| 85610 | <1% | 31,386 | $217K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,149 | $216K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,397 | $216K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,547 | $213K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,320 | $209K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,727 | $208K |
| G0378 | Hospital observation service, per hour | <1% | 4,408 | $182K |
| 82150 | <1% | 13,777 | $179K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,552 | $173K |
| 87400 | <1% | 22,460 | $168K | |
| 84703 | <1% | 7,982 | $167K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,278 | $163K |
| 93971 | <1% | 2,271 | $162K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 887 | $157K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 19,187 | $154K |
| 81001 | <1% | 32,726 | $146K | |
| 80061 | Lipid panel | <1% | 11,550 | $140K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 975 | $134K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,083 | $133K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,849 | $129K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,493 | $129K |
| 87077 | <1% | 8,670 | $117K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,699 | $114K |
| 87040 | <1% | 9,474 | $112K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,226 | $111K |
| 87088 | <1% | 15,118 | $108K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,341 | $103K |
| 70486 | <1% | 1,094 | $102K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,232 | $102K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 999 | $102K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 7,896 | $99K |
| 88304 | <1% | 1,445 | $98K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,502 | $96K |
| J3490 | Unclassified drugs | <1% | 1,629 | $96K |
| 83605 | <1% | 8,312 | $95K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,600 | $92K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 248 | $88K |
| 87522 | Neg quan hep c or qual rna | <1% | 1,955 | $88K |
| 99152 | <1% | 1,834 | $86K | |
| 87581 | <1% | 4,399 | $85K | |
| 83880 | <1% | 4,859 | $83K | |
| 87486 | <1% | 4,298 | $82K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,782 | $78K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,329 | $78K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,194 | $78K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,165 | $77K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,224 | $77K |
| 72100 | <1% | 3,541 | $76K | |
| 87186 | <1% | 6,094 | $76K | |
| 81003 | <1% | 14,169 | $76K | |
| 84439 | <1% | 6,971 | $73K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 775 | $71K |
| 96376 | <1% | 2,757 | $71K | |
| 97161 | <1% | 2,489 | $69K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 845 | $68K |
| 0099U | <1% | 534 | $68K | |
| 76937 | <1% | 263 | $67K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 3,043 | $65K |
| 81025 | <1% | 10,969 | $64K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 535 | $60K |
| 36600 | <1% | 5,072 | $59K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 7,335 | $57K |
| 87641 | <1% | 1,754 | $54K | |
| 73130 | <1% | 1,876 | $54K | |
| 86780 | <1% | 3,434 | $52K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,606 | $51K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,103 | $51K |
| 71250 | <1% | 697 | $51K | |
| 82803 | <1% | 2,972 | $48K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,630 | $46K |
| 87070 | <1% | 2,315 | $45K | |
| 86885 | <1% | 3,113 | $45K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 667 | $45K |
| 93970 | <1% | 641 | $44K | |
| 73630 | <1% | 2,357 | $44K | |
| 84100 | <1% | 6,013 | $43K | |
| 93017 | <1% | 1,002 | $43K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 572 | $42K |
| 73030 | <1% | 2,092 | $42K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,387 | $41K |
| 93976 | <1% | 475 | $40K | |
| 82607 | <1% | 3,143 | $38K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 504 | $38K |
| 74018 | <1% | 1,909 | $38K | |
| A9270 | Non-covered item or service | <1% | 14,857 | $37K |
| 86900 | <1% | 3,109 | $36K | |
| 73610 | <1% | 1,801 | $35K | |
| 76770 | <1% | 691 | $35K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,362 | $34K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 319 | $31K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 800 | $31K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,720 | $30K |
| 73564 | <1% | 1,963 | $30K | |
| 86901 | <1% | 3,197 | $30K | |
| 70491 | <1% | 184 | $30K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 156 | $29K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,288 | $29K |
| 10060 | <1% | 291 | $28K | |
| 84145 | <1% | 2,123 | $28K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 79 | $28K |
| 85379 | <1% | 3,936 | $27K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,577 | $26K |
| 72050 | <1% | 926 | $26K | |
| 82728 | <1% | 2,164 | $26K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 715 | $25K |
| 80050 | General health panel | <1% | 572 | $24K |
| 88142 | <1% | 1,009 | $24K | |
| 00840 | <1% | 61 | $23K | |
| 83540 | <1% | 2,951 | $22K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 994 | $22K |
| 87205 | <1% | 1,925 | $21K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,561 | $21K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,280 | $21K |
| 73560 | <1% | 631 | $21K | |
| 80076 | <1% | 1,518 | $20K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 60 | $19K |
| 82746 | <1% | 1,695 | $19K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,432 | $18K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,727 | $18K |
| 84702 | <1% | 1,164 | $18K | |
| 85055 | <1% | 1,110 | $18K | |
| 73110 | <1% | 790 | $18K | |
| 86706 | <1% | 1,201 | $17K | |
| 76830 | Ultrasound, transvaginal | <1% | 362 | $17K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 65 | $16K |
| 87420 | <1% | 2,520 | $16K | |
| 90715 | <1% | 737 | $15K | |
| 74022 | <1% | 466 | $15K | |
| 86803 | <1% | 840 | $15K | |
| 72070 | <1% | 498 | $15K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 43 | $14K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 262 | $14K |
| 86140 | <1% | 2,622 | $14K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 40 | $14K |
| 86708 | <1% | 779 | $14K | |
| 62323 | <1% | 244 | $14K | |
| 72040 | <1% | 250 | $14K | |
| 86762 | <1% | 632 | $14K | |
| 85651 | <1% | 2,977 | $13K | |
| 85007 | <1% | 2,227 | $13K | |
| 97165 | <1% | 766 | $13K | |
| 76536 | <1% | 281 | $12K | |
| 87340 | <1% | 836 | $12K | |
| 73502 | <1% | 737 | $12K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 161 | $12K |
| 88311 | <1% | 31 | $11K | |
| 84436 | <1% | 1,402 | $10K | |
| 72141 | <1% | 104 | $10K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,037 | $10K |
| 70496 | <1% | 132 | $10K | |
| 12001 | <1% | 148 | $10K | |
| 93880 | <1% | 264 | $10K | |
| 83970 | <1% | 371 | $10K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 860 | $10K |
| 95811 | <1% | 37 | $10K | |
| 82550 | <1% | 1,428 | $9K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 37 | $9K |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 865 | $9K |
| 72170 | <1% | 531 | $8K | |
| 82140 | <1% | 1,034 | $8K | |
| 73080 | <1% | 503 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 632 | $8K |
| 70498 | <1% | 150 | $7K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 753 | $7K |
| 93975 | <1% | 91 | $7K | |
| 84153 | <1% | 661 | $7K | |
| 97162 | <1% | 199 | $7K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 87 | $7K |
| 88342 | <1% | 115 | $7K | |
| 83525 | <1% | 503 | $7K | |
| 73590 | <1% | 591 | $7K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 687 | $7K |
| 95806 | <1% | 174 | $7K | |
| 73090 | <1% | 323 | $7K | |
| 84479 | <1% | 767 | $6K | |
| 88307 | <1% | 55 | $6K | |
| 95886 | <1% | 117 | $6K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 339 | $6K |
| J0897 | Injection, denosumab, 1 mg | <1% | 13 | $5K |
| C2629 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, laser | <1% | 34 | $5K |
| 99218 | <1% | 89 | $5K | |
| 84550 | <1% | 1,002 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 243 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,409 | $4K |
| 64493 | <1% | 18 | $4K | |
| 85044 | <1% | 1,730 | $4K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 17 | $4K |
| 87536 | <1% | 75 | $4K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 21 | $4K |
| 84481 | <1% | 360 | $3K | |
| 20553 | <1% | 31 | $3K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,262 | $3K |
| 82248 | <1% | 434 | $3K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 69 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 935 | $3K |
| 85576 | <1% | 429 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,326 | $3K |
| 72131 | <1% | 59 | $3K | |
| 87653 | <1% | 82 | $3K | |
| 87507 | <1% | 14 | $3K | |
| 72072 | <1% | 159 | $3K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 775 | $3K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 440 | $3K |
| 76870 | <1% | 73 | $3K | |
| 84156 | <1% | 1,086 | $3K | |
| 76642 | <1% | 43 | $2K | |
| 88185 | <1% | 99 | $2K | |
| 84403 | <1% | 110 | $2K | |
| 71101 | <1% | 108 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 25 | $2K |
| 77066 | Tomosynthesis, mammo | <1% | 26 | $2K |
| 00731 | <1% | 15 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,447 | $2K |
| 29125 | <1% | 27 | $2K | |
| 82044 | <1% | 310 | $2K | |
| 36430 | <1% | 14 | $2K | |
| 88184 | <1% | 56 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 42 | $2K |
| 80069 | <1% | 395 | $2K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 226 | $2K |
| 83010 | <1% | 47 | $2K | |
| 86431 | <1% | 174 | $2K | |
| 93922 | <1% | 68 | $2K | |
| 82570 | <1% | 848 | $2K | |
| 80081 | <1% | 24 | $2K | |
| 99406 | <1% | 167 | $2K | |
| 80375 | <1% | 672 | $1K | |
| 84466 | <1% | 298 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 306 | $1K |
| 72158 | <1% | 13 | $1K | |
| 82977 | <1% | 83 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 80 | $1K |
| 97116 | <1% | 164 | $1K | |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 109 | $1K |
| 83550 | <1% | 400 | $1K | |
| 82172 | <1% | 45 | $1K | |
| 82950 | <1% | 207 | $1K | |
| 83883 | <1% | 45 | $1K | |
| 99490 | Ccm add 20min | <1% | 456 | $1K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 180 | $1K |
| 82247 | <1% | 49 | $1K | |
| 84460 | <1% | 44 | $1K | |
| 12002 | <1% | 14 | $1K | |
| 96367 | <1% | 199 | $1K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 164 | $1K |
| 80164 | <1% | 99 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 241 | $1K |
| 77336 | <1% | 65 | $964.64 | |
| 90686 | <1% | 241 | $934.25 | |
| 86360 | <1% | 27 | $904.08 | |
| G0008 | Administration of influenza virus vaccine | <1% | 246 | $896.72 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 14 | $893.83 |
| 86709 | <1% | 29 | $891.21 | |
| 76775 | <1% | 32 | $839.32 | |
| 95910 | <1% | 15 | $781.66 | |
| 85520 | <1% | 214 | $767.47 | |
| 29515 | <1% | 13 | $735.23 | |
| 83655 | <1% | 63 | $702.23 | |
| 94660 | <1% | 19 | $698.56 | |
| 86038 | <1% | 70 | $688.73 | |
| 43235 | <1% | 12 | $615.00 | |
| 82565 | <1% | 175 | $596.13 | |
| 84402 | <1% | 25 | $591.86 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 348 | $581.44 |
| 96417 | <1% | 21 | $561.72 | |
| 86023 | <1% | 99 | $560.01 | |
| 76801 | <1% | 13 | $551.69 | |
| 82947 | <1% | 72 | $498.76 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15 | $468.23 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 23 | $425.38 |
| 83615 | <1% | 110 | $409.88 | |
| 72110 | <1% | 13 | $403.95 | |
| 93296 | <1% | 145 | $390.47 | |
| 87147 | <1% | 40 | $362.69 | |
| 73552 | <1% | 62 | $334.29 | |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $316.64 |
| 80143 | <1% | 46 | $294.60 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 20 | $293.65 |
| 84482 | <1% | 33 | $288.34 | |
| 88300 | <1% | 59 | $287.23 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 336 | $272.09 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 37 | $271.69 |
| 84520 | <1% | 88 | $257.66 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 818 | $247.26 |
| 86920 | <1% | 20 | $214.19 | |
| 84146 | <1% | 12 | $210.15 | |
| 84480 | <1% | 19 | $206.05 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 135 | $191.20 |
| 51798 | <1% | 26 | $189.13 | |
| 82043 | <1% | 84 | $183.58 | |
| 87430 | <1% | 86 | $176.67 | |
| 73060 | <1% | 15 | $170.77 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 582 | $166.98 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 477 | $165.32 |
| 85014 | <1% | 126 | $164.86 | |
| 85018 | <1% | 177 | $163.54 | |
| 72120 | <1% | 12 | $160.09 | |
| 70360 | <1% | 12 | $138.93 | |
| 74019 | <1% | 16 | $132.79 | |
| 96415 | <1% | 17 | $132.09 | |
| 84165 | <1% | 17 | $127.05 | |
| 36591 | <1% | 41 | $125.52 | |
| 73522 | <1% | 13 | $110.63 | |
| C1758 | Catheter, ureteral | <1% | 13 | $110.00 |
| 86308 | <1% | 13 | $87.95 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 262 | $67.30 |
| 51702 | <1% | 32 | $67.11 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 51 | $61.63 |
| 82040 | <1% | 15 | $51.25 | |
| 87210 | <1% | 13 | $50.82 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 191 | $43.57 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 28 | $42.65 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 21 | $39.36 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 13 | $37.79 |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 78 | $34.94 |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 27 | $21.24 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 28 | $19.57 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 72 | $11.65 |
| 99439 | <1% | 15 | $10.08 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 40 | $2.16 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 83 | $1.51 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 29 | $0.73 |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 21 | $0.32 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 20 | $0.03 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 12 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 61 | $0.00 |
| 80349 | 0% | 22 | $0.00 | |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSWEARINGEN, ANGELA (COO)